MiMedx Group (NASDAQ:MDXG) Given "Hold (C)" Rating at Weiss Ratings

Key Points

• MiMedx Group's stock received a "hold (C)" rating from Weiss Ratings, while Wall Street Zen upgraded it to a "strong-buy."
• The stock currently has a consensus target price of $12.00 and is trading at approximately $7.10, down 2.2% recently.
• In its latest earnings report, MiMedx Group posted an EPS of $0.10, surpassing expectations, and reported revenue of $98.61 million for the quarter.

MiMedx Group (NASDAQ:MDXG - Get Free Report)'s stock had its "hold (c)" rating reiterated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also recently weighed in on MDXG. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Cantor Fitzgerald raised their target price on MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

MiMedx Group Stock Down 2.2%

MDXG stock opened at $7.10 on Wednesday. The company's 50 day moving average price is $7.10 and its 200 day moving average price is $6.85. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 33.81 and a beta of 1.73. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.90 and a current ratio of 4.39.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.06 by $0.04. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The company had revenue of $98.61 million during the quarter, compared to analysts' expectations of $90.79 million. On average, equities research analysts anticipate that MiMedx Group will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

Large investors have recently bought and sold shares of the company. Rhumbline Advisers raised its holdings in MiMedx Group by 1.4% during the first quarter. Rhumbline Advisers now owns 177,156 shares of the company's stock worth $1,346,000 after purchasing an additional 2,436 shares in the last quarter. Sowell Financial Services LLC acquired a new position in MiMedx Group during the first quarter worth $115,000. Palumbo Wealth Management LLC grew its holdings in MiMedx Group by 33.6% during the first quarter. Palumbo Wealth Management LLC now owns 23,765 shares of the company's stock worth $181,000 after acquiring an additional 5,980 shares during the period. HighMark Wealth Management LLC raised its position in MiMedx Group by 1,333.3% in the first quarter. HighMark Wealth Management LLC now owns 43,000 shares of the company's stock worth $327,000 after acquiring an additional 40,000 shares in the last quarter. Finally, OneDigital Investment Advisors LLC boosted its position in shares of MiMedx Group by 3.9% during the 1st quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company's stock worth $419,000 after purchasing an additional 2,056 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.